Songcheng Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Songcheng Yu has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Yongjun Wu
13 shared publicationsLihua Ding
7 shared publications- Chongjian Wang
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, PR China
6 shared publications Leiliang He
College of Public Health, Zhengzhou University, Zhengzhou 450001, China
6 shared publicationsXueying Lei
College of Public Health, Zhengzhou University, Zhengzhou, 450001, China
6 shared publications- Yongjun Wu
Zhengzhou University
6 shared publications
Latest Publications
- 20 August 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (32) , 6823-6830
Signal logic gate mediated by a controllable CRISPR/Cas12a system for simultaneous detection of DNA mutation and methylation
A CRISPR/Cas12a biosensor with crRNA-titrated logic gates enables simultaneous detection of DNA mutation and methylation, while GlaI cleavage eliminates bisulfite pretreatment for methylated DNA.
- 20 August 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (32) , 6823-6830
Signal logic gate mediated by a controllable CRISPR/Cas12a system for simultaneous detection of DNA mutation and methylation
A CRISPR/Cas12a biosensor with crRNA-titrated logic gates enables simultaneous detection of DNA mutation and methylation, while GlaI cleavage eliminates bisulfite pretreatment for methylated DNA.
- 6 August 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (9) , 5887-5897
Stimuli-Responsive DNA Tetrahedral Lysosome-Targeting Chimeras for Enhanced HER2 Protein Degradation
Overexpression and abnormal activation of membrane proteins promote malignant tumor cell proliferation, while traditional interventions are often limited by drug resistance caused by target mutations. Here, we designed a stimulus-responsive DNA tetrahedron lysosome-targeted chimera (tFNA-LYTAC) strategy for degrading embrane proteins. Two tetrahedra are modified with trivalent HER2 aptamers (tFNA1-Apt) and trivalent IGF2R aptamers (tFNA2-Apt), enabling targeted binding to HER2 and IGF2R, and are then self-assembled into tFNA-LYTAC under VEGF stimulation to promote HER2 degradation. The trivalent aptamer modification strategy significantly enhances the overall binding capacity of tFNA1-Apt to cells. Importantly, tFNA-LYTAC formed only in the presence of VEGF, integrating tetrahedral multivalent aptamer targeting with stimulus responsiveness to improve the degradation specificity. VEGF-responsive tFNA-LYTAC promoted HER2 degradation and suppressed the phosphorylation of key downstream signaling proteins. The study innovatively proposes a “target recognition-stimulus response-endocytic degradation” mode that selectively regulates membrane proteins through programmable multivalent aptamer nanostructures.
- 6 August 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (9) , 5887-5897
Stimuli-Responsive DNA Tetrahedral Lysosome-Targeting Chimeras for Enhanced HER2 Protein Degradation
Overexpression and abnormal activation of membrane proteins promote malignant tumor cell proliferation, while traditional interventions are often limited by drug resistance caused by target mutations. Here, we designed a stimulus-responsive DNA tetrahedron lysosome-targeted chimera (tFNA-LYTAC) strategy for degrading embrane proteins. Two tetrahedra are modified with trivalent HER2 aptamers (tFNA1-Apt) and trivalent IGF2R aptamers (tFNA2-Apt), enabling targeted binding to HER2 and IGF2R, and are then self-assembled into tFNA-LYTAC under VEGF stimulation to promote HER2 degradation. The trivalent aptamer modification strategy significantly enhances the overall binding capacity of tFNA1-Apt to cells. Importantly, tFNA-LYTAC formed only in the presence of VEGF, integrating tetrahedral multivalent aptamer targeting with stimulus responsiveness to improve the degradation specificity. VEGF-responsive tFNA-LYTAC promoted HER2 degradation and suppressed the phosphorylation of key downstream signaling proteins. The study innovatively proposes a “target recognition-stimulus response-endocytic degradation” mode that selectively regulates membrane proteins through programmable multivalent aptamer nanostructures.
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Orthogonal Cas13a/Cas12a Cascade for One-Pot Amplification-Free Detection of miRNA-21
MicroRNAs (miRNAs) are promising biomarkers for clinical diagnosis and disease monitoring. However, current CRISPR/Cas-based miRNA sensors generally require reverse transcription or nucleic acid amplification to improve sensitivity, which complicates the workflow and increases the risk of contamination, nonspecific amplification, and false-positive results. Herein, we developed a one pot amplification-free Cas13a/Cas12a cascade platform based on a designed dual-functional molecular bridge probe, Conv HP-3, which served as both a substrate for Cas13a-mediated trans-cleavage and an activator for Cas12a-mediated trans-cleavage, thereby linking target recognition to cascade signal amplification for miRNA-21 detection. Following the introduction of miRNA-21, Cas13a was specifically activated through target-crRNA recognition and cleaved the Conv HP-3 probe to release a Cas12a-activating DNA fragment. This fragment subsequently triggered Cas12a-mediated cleavage of the ssDNA reporter, generating a markedly enhanced fluorescence signal. This fluorescence biosensor enabled quantitative detection of miRNA-21 from 1 to 1000 pmol/L within 60 min, with a low detection limit of 0.66 pM. Notably, the assay achieved average recoveries ranging from 95.97% to 108.59%, with a variation between 0.6% and 1.78%, demonstrating its good accuracy and precision. This biosensing platform shows great promise for the rapid and sensitive detection of miRNAs in clinical applications.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOrthogonal Cas13a/Cas12a Cascade for One-Pot Amplification-Free Detection of miRNA-21
MicroRNAs (miRNAs) are promising biomarkers for clinical diagnosis and disease monitoring. However, current CRISPR/Cas-based miRNA sensors generally require reverse transcription or nucleic acid amplification to improve sensitivity, which complicates the workflow and increases the risk of contamination, nonspecific amplification, and false-positive results. Herein, we developed a one pot amplification-free Cas13a/Cas12a cascade platform based on a designed dual-functional molecular bridge probe, Conv HP-3, which served as both a substrate for Cas13a-mediated trans-cleavage and an activator for Cas12a-mediated trans-cleavage, thereby linking target recognition to cascade signal amplification for miRNA-21 detection. Following the introduction of miRNA-21, Cas13a was specifically activated through target-crRNA recognition and cleaved the Conv HP-3 probe to release a Cas12a-activating DNA fragment. This fragment subsequently triggered Cas12a-mediated cleavage of the ssDNA reporter, generating a markedly enhanced fluorescence signal. This fluorescence biosensor enabled quantitative detection of miRNA-21 from 1 to 1000 pmol/L within 60 min, with a low detection limit of 0.66 pM. Notably, the assay achieved average recoveries ranging from 95.97% to 108.59%, with a variation between 0.6% and 1.78%, demonstrating its good accuracy and precision. This biosensing platform shows great promise for the rapid and sensitive detection of miRNAs in clinical applications.
- 30 April 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 360, 128016
Direct microRNA detection via topologically engineered CRISPR/Cas12a cascade amplification assay
- 30 April 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 360, 128016
Direct microRNA detection via topologically engineered CRISPR/Cas12a cascade amplification assay
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (4) , 1208-1214
A multifunctional switch for label-free CRISPR/Cas12a sensor with self-driven amplification
MicroRNA (miRNA) is promising candidate for non-invasive diagnostic biomarker. Conventional CRISPR/Cas12a-based miRNA detection systems are constrained by reliance on reverse transcription, nucleic acid pre-amplification and costly fluorescently labeled reporters which introduce chemical modification complexity and background noise. To address these limitations, we herein developed a multifunctional switch that integrated target recognition, CRISPR/Cas12a system activation, intrinsic fluorescence signaling, and autonomous signal amplification within a single molecular architecture. As a proof of concept, this switch enabled a label-free CRISPR/Cas12a biosensing for miR-21 detection with a detection limit of 4.8 nM and robust performance in accuracy, precision, and selectivity. This proposed label-free CRISPR/Cas12a platform could be applied for real sample and is a promising candidate for point-of-care miRNA detection.
- 1 December 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (4) , 1208-1214
Open AccessA multifunctional switch for label-free CRISPR/Cas12a sensor with self-driven amplification
MicroRNA (miRNA) is promising candidate for non-invasive diagnostic biomarker. Conventional CRISPR/Cas12a-based miRNA detection systems are constrained by reliance on reverse transcription, nucleic acid pre-amplification and costly fluorescently labeled reporters which introduce chemical modification complexity and background noise. To address these limitations, we herein developed a multifunctional switch that integrated target recognition, CRISPR/Cas12a system activation, intrinsic fluorescence signaling, and autonomous signal amplification within a single molecular architecture. As a proof of concept, this switch enabled a label-free CRISPR/Cas12a biosensing for miR-21 detection with a detection limit of 4.8 nM and robust performance in accuracy, precision, and selectivity. This proposed label-free CRISPR/Cas12a platform could be applied for real sample and is a promising candidate for point-of-care miRNA detection.
- 29 July 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 288, 117834
cliCRISPR: crRNA-limited CRISPR/Cas12a system for multiplexed detection
- 29 July 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 288, 117834
cliCRISPR: crRNA-limited CRISPR/Cas12a system for multiplexed detection